Status:
UNKNOWN
Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial
Lead Sponsor:
Peshawar Institute of Cardiology
Collaborating Sponsors:
Getz Pharma
Conditions:
Left Ventricular Thrombus
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The investigators aimed to design this randomized control trial to compare rivaroxaban and apixaban with warfarin in Left ventricular thrombus resolution by * Success rate of left ventricular thrombu...
Detailed Description
1. TITLE: Safety and efficacy of Rivaroxaban and Apixaban in comparison to Warfarin in Left ventricular clot- clinical trial 2. INTRODUCTION: Left ventricular thrombus (LVT) is a known life th...
Eligibility Criteria
Inclusion
- Inclusion criteria
- All hemodynamically stable patients with LV thrombus on echocardiogram after.
- Exclusion criteria
- Chronic Liver Disease (CLD) patients
- Creatinine clearance less than 15ml/min
- Recent Hemorrhagic stroke
- Thrombocytopenia, platelets \<50k or anemia with baseline HB \<9mg/dl
- Recent Major GI bleed
- History of atrial fibrillation and mitral stenosis
- History of deep vein thrombosis/pulmonary embolism and Patients already on anticoagulation
Exclusion
Key Trial Info
Start Date :
May 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
141 Patients enrolled
Trial Details
Trial ID
NCT05973188
Start Date
May 1 2023
End Date
June 30 2024
Last Update
August 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peshawar Institute of Cardiology
Peshawar, KPK, Pakistan, 25000